Thomas Brodowicz Selected Research

pazopanib

3/2021	Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient® in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06).
1/2020	A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
5/2016	Pazopanib in Primary Cardiac Angiosarcoma of the Right Atrium: A Case Report.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Brodowicz Research Topics

Disease

25	Sarcoma (Soft Tissue Sarcoma) 01/2024 - 04/2002
24	Neoplasms (Cancer) 01/2024 - 03/2003
16	Breast Neoplasms (Breast Cancer) 09/2016 - 09/2003
10	Disease Progression 12/2017 - 03/2004
8	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 07/2010
8	Leiomyosarcoma 01/2023 - 06/2014
7	Liposarcoma 01/2024 - 06/2014
7	Neoplasm Metastasis (Metastasis) 01/2021 - 05/2003
6	Neutropenia 11/2017 - 10/2009
6	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 10/2013 - 01/2009
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2012 - 05/2006
4	Hypertension (High Blood Pressure) 01/2020 - 02/2013
3	Nausea 11/2017 - 04/2002
3	Hand-Foot Syndrome 09/2016 - 02/2013
2	Hemangiosarcoma (Angiosarcoma) 03/2021 - 05/2016
2	Synovial Sarcoma (Synovioma) 01/2018 - 12/2016
2	Spinal Cord Compression 12/2017 - 04/2012
2	Spontaneous Fractures (Pathological Fracture) 12/2017 - 04/2012
2	Peripheral Nervous System Diseases (PNS Diseases) 09/2016 - 02/2013
2	Pain (Aches) 01/2015 - 03/2012
2	Osteonecrosis (Kienbock's Disease) 01/2015 - 08/2013
2	Hyperthermia 09/2014 - 11/2011
2	Adenocarcinoma 10/2013 - 06/2008
2	Fatigue 03/2012 - 10/2009
1	Inflammation (Inflammations) 01/2021
1	Ewing Sarcoma (Sarcoma, Ewing) 02/2020
1	Lymphopenia (Lymphocytopenia) 01/2020
1	Melanoma (Melanoma, Malignant) 01/2019
1	Chondrosarcoma 10/2018
1	Prostatic Neoplasms (Prostate Cancer) 12/2017
1	Hypercalcemia (Milk Alkali Syndrome) 12/2017
1	Pneumonia (Pneumonitis) 11/2017
1	Drug-Related Side Effects and Adverse Reactions 11/2017
1	Febrile Neutropenia 11/2017
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2017
1	Ovarian Neoplasms (Ovarian Cancer) 01/2017
1	Liver Failure 12/2016
1	Asthenia 12/2016
1	Hypersensitivity (Allergy) 05/2016
1	Diarrhea 02/2016

Drug/Important Bio-Agent (IBA)

10	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2015
6	Cetuximab (Erbitux)FDA Link 01/2023 - 07/2010
6	Paclitaxel (Taxol)FDA LinkGeneric 03/2021 - 03/2002
6	regorafenibIBA 12/2020 - 03/2015
6	Bevacizumab (Avastin)FDA Link 01/2017 - 07/2012
6	Trastuzumab (Herceptin)FDA Link 02/2016 - 12/2003
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 04/2002
5	AnthracyclinesIBA 12/2016 - 01/2010
4	TrabectedinIBA 01/2024 - 08/2013
4	Capecitabine (Xeloda)FDA Link 09/2016 - 01/2011
4	Pemetrexed (MTA)FDA Link 09/2012 - 10/2009
3	pazopanib FDA Link 03/2021 - 05/2016
3	C-Reactive ProteinIBA 10/2018 - 01/2015
3	Denosumab FDA Link 01/2015 - 04/2012
3	Epirubicin (Ellence)FDA LinkGeneric 01/2011 - 03/2005
3	Docetaxel (Taxotere)FDA Link 01/2011 - 06/2008
3	Gemcitabine FDA Link 01/2010 - 03/2005
2	eribulin FDA Link 01/2024 - 01/2023
2	Transaminases (Aminotransferases)IBA 01/2020 - 06/2014
2	AntigensIBA 01/2019 - 12/2003
2	AlbuminsIBA 12/2017 - 03/2016
2	Serum AlbuminIBA 12/2017 - 03/2016
2	CreatinineIBA 12/2017 - 03/2016
2	Codon (Codons)IBA 06/2015 - 01/2012
2	Antineoplastic Agents (Antineoplastics)IBA 06/2014 - 10/2009
2	AntibodiesIBA 10/2013 - 12/2003
2	Diphosphonates (Bisphosphonates)IBA 08/2013 - 04/2012
2	Hormones (Hormone)IBA 02/2013 - 04/2012
2	Monoclonal AntibodiesIBA 04/2012 - 12/2003
2	PlatinumIBA 03/2012 - 10/2009
2	Type II DNA Topoisomerases (Topoisomerase II)IBA 01/2012 - 01/2011
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2008 - 06/2008
2	CytokinesIBA 09/2003 - 05/2001
1	olaratumabIBA 01/2021
1	ORALIT (ORS)IBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Immune Checkpoint ProteinsIBA 01/2021
1	Unithiol (DMPS)IBA 01/2021
1	Growth Factor ReceptorsIBA 01/2021
1	Transcription Factors (Transcription Factor)IBA 02/2020
1	Co-Repressor ProteinsIBA 02/2020
1	Radioisotopes (Radionuclides)IBA 12/2017
1	Radium-223IBA 12/2017
1	Fibrinogen (Factor I)FDA Link 11/2017
1	NivolumabIBA 01/2017
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2016
1	Taxoids (Taxanes)IBA 05/2016
1	Vinorelbine (Navelbine)FDA LinkGeneric 02/2016
1	Lapatinib (GW572016)FDA Link 02/2016
1	Tyrosine Kinase InhibitorsIBA 02/2016

Therapy/Procedure

26	Drug Therapy (Chemotherapy) 01/2024 - 04/2002
19	Therapeutics 01/2024 - 03/2004
4	Adjuvant Chemotherapy 01/2012 - 03/2003
3	Radiotherapy 12/2017 - 11/2010
2	Extracorporeal Circulation 09/2014 - 11/2011
2	Aftercare (After-Treatment) 03/2013 - 01/2009
2	Neoadjuvant Therapy 01/2011 - 03/2004
1	Castration 12/2017
1	Radiofrequency Ablation 12/2017
1	Salvage Therapy 01/2017